Huntington's disease (HD) is a neurodegenerative disorder characterized by progressive neuronal death in the basal ganglia and cortex. Although increasing evidence supports a pivotal role of mitochondrial dysfunction in the death of patients' neurons, the molecular bases for mitochondrial impairment have not been elucidated. We provide the first evidence of an abnormal activation of the Bcl-2/adenovirus E1B 19-kDa interacting protein 3 (BNip3) in cells expressing mutant Huntingtin. In this study, we show an abnormal accumulation and dimerization of BNip3 in the mitochondria extracted from human HD muscle cells, HD model cell cultures and brain tissues from HD model mice. Importantly, we have shown that blocking BNip3 expression and dimerization restores normal mitochondrial potential in human HD muscle cells. Our data shed light on the molecular mechanisms underlying mitochondrial dysfunction in HD and point to BNip3 as a new potential target for neuroprotective therapy in HD. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits distribution and reproduction in any medium, provided the original author and source are credited. Creation of derivative works is permitted but the resulting work may be distributed only under the same or similar license to this one. This license does not permit commercial exploitation without specific permission.
Huntington's disease (HD) is a neurodegenerative disorder caused by a poly-glutamine (poly-Q) expansion in the protein known as Huntingtin (htt). The neurons of HD patients progressively die as the disease progresses, leading to widespread atrophy of the striatum and cortex, which account for the clinical symptoms of the disease.
Studies on the central nervous system (CNS) and peripheral tissues of HD patients, as well as in animal and cell culture models of HD, have identified several mitochondrial abnormalities, including a decreased activity of respiratory chain enzymatic complexes, a decreased ATP/ADP ratio and an altered morphology of these organelles. [1] [2] [3] [4] [5] Mitochondria have an essential role in the physiology of eukaryotic cells; not only do they produce most of the cell's ATP but they also participate in ion homeostasis, regulation of the cell's redox state, lipid and amino-acid metabolism, as well as in regulation of programmed cell death. All these functions are highly dependent on the mitochondrial electrochemical transmembrane potential (Dc m ), a physicochemical parameter consisting of two components, namely the total transmembrane electrical potential (voltage gradient) and the proton gradient that is physiologically generated across the inner mitochondrial membrane by the activity of the respiratory chain. Growing evidence indicates that the many mitochondrial abnormalities observed in HD tissues may stem from an abnormal Dc m , as the mitochondria extracted from HD patients had Dc m values lower than the mitochondria from normal patients. [6] [7] [8] [9] Dc m loss seems to be a direct effect of mutant htt, given that it occurs in normal cells transfected with mutant htt 10, 11 and when mutant htt is added to mitochondria isolated from normal brains. 12 The results from these studies notwithstanding, the molecular bases for the Dc m decrease observed in HD cells still remain elusive.
Bcl-2/adenovirus E1B 19-kDa interacting protein 3 (BNip3) is a member of the so-called BH3-only subfamily of Bcl-2 family proteins that regulate the permeability state of the outer mitochondrial membrane (OMM). This regulation is accompanied by the formation of homo-and hetero-oligomers inside the membrane, which influences Dc m and controls cell death mechanisms. 13, 14 The BNip3 protein is normally present in the brain tissue and skeletal muscle 15 and is mainly localized in the cytoplasm and nucleus or is found loosely associated with the mitochondrial membrane in an inactive conformation. 16, 17 The molecular mechanism underlying BNip3 activation is not completely understood, but it probably involves a multi-step process. A few intracellular toxic stimuli, such as decreased intracellular pH and increased cytosolic calcium concentration, 17, 18 can induce BNip3 integration into the OMM with the protein's N terminus in the cytoplasm and C terminus inside the mitochondria. 19 The BNip3 C-terminal hydrophobic domain is required for integration in the OMM, as its deletion prevents the mutant protein (BNip3DTM) from integrating into the OMM and inducing cell death. 20, 21 Importantly, BNip3DTM functions as a dominant-negative mutant, interacting with wild-type BNip3 and blocking its integration into the OMM. [22] [23] [24] Once integrated into the OMM, BNip3 can self-associate and form stable homodimers on the basis of intermonomeric helix-helix polar interactions of various side chains. 25 The unique structure of the transmembrane domain suggests that BNip3 dimers could function as proton channels in the OMM, thereby increasing ion conductance. 25 Considering the crucial role of BNip3 in regulating OMM permeability, we have undertaken a study to investigate the potential role of BNip3 in the mitochondrial dysfunction induced by mutant htt.
Results
Increased BNip3 levels and mitochondrial localization in muscle cells from HD patients. We have previously shown that myoblasts isolated from HD patients show mitochondrial dysfunction. 8 To investigate the potential role of BNip3, we analyzed its expression levels in muscle cell lysates from four HD and four control subjects by SDS-PAGE. The molecular weight of BNip3, as predicted from its amino-acid sequence, is 21.5 kDa; however, the protein has been described to migrate as two major molecular species, with apparent molecular weights of B30 and B60 kDa in SDS-PAGE gels, representing monomeric and dimeric forms, respectively. 26, 27 The apparent molecular weight of monomeric BNip3 in SDS-PAGE and the presence of multiple protein bands at B30 kDa are likely due to protein phosphorylation, as BNip3, similar to many proteins of the Bcl-2 family, bears consensus sites for phosphorylation by protein kinases (Supplementary Figure 1) . 18 The biological role of these possible posttranslational modifications still remains unknown. The BNip3 signal at B60 kDa, corresponding to BNip3 dimers, can be detected by SDS-PAGE, as BNip3 dimers are highly stable and resistant to detergents. 26, 28 In cell lysates from human HD myoblasts, we detected monomeric BNip3. Densitometric analysis showed higher levels of monomeric BNip3 in HD myoblasts than in myoblasts extracted from control subjects. Dimeric BNip3 was barely detectable in total lysates of human myoblasts ( Figure 1a) .
As the pivotal step in BNip3-mediated cell death involves its integration into the OMM, 19 we tested whether the increased expression of BNip3 resulted in increased mitochondrial localization. Mitochondria-enriched fractions were prepared from normal and HD human muscle cells and then treated by alkaline pH. This treatment detaches loosely associated peripheral membrane proteins, thus enriching the samples for mitochondrial transmembrane proteins. 29 Immunoblot analysis of alkali-treated mitochondrial fractions showed strong monomeric BNip3 signals in both HD and control myoblasts. However, there was a trend of increased monomeric BNip3 in HD samples. The dimeric form of BNip3 was visible only in the HD mitochondria and was not detectable in control myoblasts (Figure 1b) . HD myoblasts derived from patients carrying 60 CAG repeats (lane 6) had the highest dimeric BNip3 signal.
To confirm the increased association of BNip3 with the HD mitochondria, we performed confocal microscopy on myoblasts obtained from control and HD patients. Notably, BNip3 colocalized with the mitochondria in B40% of HD cells, while the protein was mainly localized in the cytoplasm and in the nucleus in control cells (Figure 1c and Supplementary  Figure 2) .
Overall, our data suggest the accumulation and dimerization of BNip3 protein in the mitochondria of human HD muscle cells.
BNip3 levels in the brain tissue from R6/2 and YAC128 mouse models. To investigate whether the changes observed in BNip3 expression and localization in muscle cells obtained from HD patients mirrored events occurring in the CNS, we analyzed BNip3 levels and localization patterns in the brain tissues of two different HD model mice, namely R6/2 and yeast artificial chromosome (YAC)128. R6/2 mice are transgenic for exon-1 of the human IT15 gene, containing highly expanded CAG repeats, 30 whereas YAC128 mice express a full-length IT15 gene with 128 CAG repeats. 31 There was a trend of decreased monomeric BNip3 in HD striatum samples ( Figure 2a) ; no significant difference in BNip3 expression was observed in the cortex from R6/2 and littermate control mice at 10 weeks of age (Figure 2b ). It is noteworthy that immunoblotting analysis of alkali-treated mitochondrial fractions showed a stronger dimeric BNip3 signal in the R6/2 striatum than in the wild-type striatum (Figure 2c ). In R6/2 mitochondrial fractions, we also observed an anti- BNip3-immunoreactive band with an apparent molecular weight 460 kDa, which is consistent with previously described higher-order oligomeric forms of BNip3. 14, 32 Immunoblotting analysis of cortical mitochondrial fractions showed a slight increase in the dimeric BNip3 signal in the R6/2 striatum than in the wild-type striatum, In the striatum of 6-month-old YAC128 mice, levels of monomeric and dimeric BNip3 were significantly increased with respect to control littermates ( Figure 2e ). Expression levels in the cortex showed a high degree of variability among the animals analyzed, and mean differences between control and HD mice did not reach statistical significance (Figure 2f) . However, the variance in the distribution of BNip3 levels in the HD group was significantly different from the variance in the control group of animals, suggesting a trend toward increased BNip3 levels in HD cortexes. Similar to R6/2 animals, the mitochondria from the YAC128 striatum contained more BNip3 than those from the control striatum (Figure 2g ). No difference in BNip3 level was detected between the YAC128 cortical mitochondria and the mitochondria from control cortexes (Figure 2h ).
Expression of mutant htt induces the accumulation of monomeric BNip3, BNip3 dimerization and BNip3 integration into the OMM in HD cell culture models. To investigate whether the observed alteration of BNip3 levels in HD myoblasts and HD mouse models was the direct result of mutant htt expression, we transfected the neuroblastoma cell line, SHSY5Y, with a plasmid encoding exon-1 of wildtype (SHSY5Y-htt-wt) or mutant (SHSY5Y-htt-mut) htt (Figure 3a) . Immunoblotting analysis of whole-cell lysates showed that mutant htt caused an accumulation of monomeric and dimeric BNip3 (Figure 3b, line 3) .
To investigate whether mutant htt expression also promoted BNip3 integration into the mitochondrial membrane, we isolated mitochondria from SHSY5Y-htt-wt and SHSY5Y-httmut cells and treated them with alkali. Under these conditions, significant amounts of BNip3 dimers and oligomers were detectable in the mitochondria from SHSY5Y-htt-mut cells, but not from cells transfected with normal htt (Figure 3c ).
To further confirm that mutant htt induced BNip3 integration into mitochondrial membranes, we analyzed an additional model cell line. HEK293T cells express barely detectable levels of endogenous BNip3 under normal growth conditions; 33 therefore, we conducted cotransfection experiments of the plasmid encoding htt, together with the plasmid encoding BNip3.
As a negative control, we transfected the mutant BNip3DTM, which lacks the C-terminal domain essential for integration into the OMM. At 72 h after transfection, wild-type (Figure 3e , right panel) either in HEK293T-htt-wt or in HEK293T-htt-mut cells; indeed, BNip3DTM was detected as two bands of B28 kDa, as previously shown. 26 These data are in agreement with previous reports showing that the transmembrane domain of BNip3 is required for its dimerization. 20, 26 We also analyzed alkali-treated mitochondrial fractions. HEK293T-htt-mut cells had higher BNip3 signals in their mitochondria than did HEK293T-htt-wt cells (Figure 3f ). Both monomeric and dimeric BNip3 significantly increased in cells expressing mutated htt. BNip3DTM was not detected in mitochondrial fractions, in agreement with previous reports showing that the transmembrane domain of BNip3 is required for its complete integration into the mitochondrial membrane. 20 Increased resistance of monomeric BNip3 in HD samples to proteinase-K digestion. One proposed model to explain BNip3 function posits that BNip3 can exist as an inactive, latent monomer, which requires a death activation signal to become active. 28 The death signal elicits a conformational change in monomeric BNip3 that promotes protein dimerization or oligomerization in the lipid environment of the mitochondrial membrane and the formation of an ion-permeable channel through the OMM. 25 Thus, a conformational change in the monomeric form is believed to be the triggering event in BNip3 activation and mitochondrial membrane permeabilization. To assess potential differences in the conformational state of monomeric BNip3 induced by mutant htt, we tested BNip3 resistance to in vitro digestion with proteinase-K (PK) in whole extracts of HD samples. This approach has been successfully used to discriminate between inactive (more prone to digestion) and active (more resistant) forms of monomeric BNip3 in a previous study. 14 The increased resistance of the active monomeric form to PK digestion is presumably due to the acquisition of a proteolysis-resistant conformation.
14 Total lysates prepared from control and HD myoblasts were digested with increasing concentrations of PK, and the products were analyzed by immunoblotting. As shown in Figure 4a , BNip3 monomers in cell lysates from HD myoblasts were significantly more resistant to PK digestion than those from control samples. Actin digestion was not different between HD and control samples (Figure 4a) , demonstrating that the increased resistance to proteolysis in HD samples was specific for the BNip3 protein. Similar results were obtained using total protein extracts from R6/2 and control mouse brains (Figure 4b) . Overall, our data support the hypothesis that mutant htt promotes a conformational change in the BNip3 protein that may trigger its activation. To further confirm that BNip3 activation on mutated htt involve a posttrascriptional mechanism, we analyzed the transcriptional expression Overexpression of the mutant protein BNip3DTM and silencing of endogenous BNip3 protect cells from the mitochondrial depolarization induced by mutant htt. We have previously shown that human HD myoblasts show important features of mitochondrial dysfunction, with Dc m decreased by B30% compared with control myoblasts. 8 As BNip3 integration into the OMM can elicit the reduction of Dc m on various toxic stimuli, 15 we hypothesized that the high BNip3 levels we found associated with mitochondrial membrane fractions in HD cells could cause a decrease in Dc m , previously observed in HD myoblasts and other HD models. 6, 8, 10, 11 In this context, we reasoned that blocking both BNip3 integration in the OMM and BNip3 dimerization by overexpression of the dominant-negative protein BNip3DTM would protect cells from the mitochondrial depolarization induced by mutant htt. The mutant BNip3DTM lacks the C-terminal domain essential for integration into the OMM and has been shown to function as a dominant-negative mutant that blocks BNip3 translocation and integration into the OMM. Figure 4 Increased resistance of monomeric BNip3 to proteinase-K digestion in HD cells. Total cell extracts from four human myoblasts (a) and three R6/2 mouse brains (b) were digested in vitro for 8 min with increasing concentrations of PK: 0.05 mg/ml (lane 2), 0.1 mg/ml (lane 3), 0.2 mg/ml (lane 4) and 0.4 mg/ml (lane 5); lane 1 contained the untreated sample. Lysis buffer contained 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 mg/ml pepstatin, 1 mg/ml leupeptin and 20 mM MG132. Densitometric analysis was performed on monomeric BNip3 signals (Clone ANa40). Multiple bands corresponding to monomeric forms were analyzed together. Data are reported as means±S.E.M., as percentages of the untreated sample. Monomeric BNip3 extracted from HD samples demonstrated increased resistance to PK digestion (*Po0.05 versus control sample). No difference in actin digestion patterns was detected between HD and control samples
22,23
In human HD myoblasts, transient transfection with BNip3DTM did not modify mitochondrial Dc m both in control and HD myoblasts (data not shown), probably because of high endogenous levels of BNip3 and the low transfection efficiency of plasmid DNA in primary myoblasts (B60% of cells displayed green fluorescence 24 h after trasfection with the pEGFP vector). However, cotransfection of cells with BNip3DTM and with short interfering RNA (siRNA) to knock down endogenous BNip3 resulted in an efficient silencing of the endogenous protein (by B70%, Figure 5a ), in a detectable expression of BNIP3DTM, as well as in a significant increase in Dc m in all four HD lines transfected (mean value 124%, **Po0.01; Figures 5b and c) .
Overall, these results suggest that the Dc m loss in HD myoblasts may stem from BNip3 activation.
Discussion
Evidence that accrued over the past few years increasingly favors the hypothesis that mitochondrial dysfunction has a key function in the death of the neuronal cells of HD patients. 34, 35 Nevertheless, the nature of such mitochondrial damage has remained elusive so far. Our results suggest a role of BNip3 protein in the mitochondrial dysfunction induced by mutated htt. Clinical and experimental studies have provided convincing evidence that mitochondrial dysfunction occurs in the CNS and skeletal muscle tissue of HD patients. 4, 34, 36, 37 Thus, cultures of human myoblasts obtained from HD patients are an excellent model to study the pathogenic effects of mutated htt on the mitochondria. Our former study showed a pathological decrease of Dc m in HD myoblasts. 8 In this study, we provide evidence that BNip3 levels are increased in total lysates of HD myoblasts. More importantly, we demonstrate that more BNip3 colocalized with the mitochondria in human HD myoblasts when compared with age-matched control myoblasts. The increased total level of the BNip3 protein might depend both on transcriptional and on posttranscriptional regulation. However, results indicating increased BNip3 translocation into the mitochondria and BNip3 integration into the OMM in HD cells suggest that posttranscriptional mechanisms are primarily involved. This hypothesis is further supported by the finding that the BNip3 protein in HD myoblasts is more resistant to PK digestion compared with that in control samples, probably because of the acquisition of an alternative conformation as a prelude to BNip3 activation. 14 The results obtained from human HD myoblasts were confirmed in the brain tissue extracted from two different animal models of HD, R6/2 and YAC128 mice. In both animal models, we observed increased levels of dimeric BNip3 associated with striatal mitochondrial fractions. Importantly, YAC128 mice showed increased BNip3 levels in the striatum at 6 months of age when, in spite of overt motor symptoms, no striatal tissue loss had yet occurred. This suggests that alterations in BNip3 localization and activity may precede neural loss in HD. In addition, the transient expression of mutant htt in SHSY5Y cells induced BNip3 accumulation and translocation into the OMM, thus confirming that this phenomenon occurs in neuronal cells and is directly triggered by mutant htt. Unfortunately, a study on BNip3 in human HD brains cannot be conducted, as BNip3 expression and activation are strongly induced by hypoxic conditions that inevitably precede the collection of autopsy specimens.
A large number of studies using cell culture models have shown that BNip3 integration into the OMM leads to a potential loss of mitochondria. 19, 21, 23, 38 In accordance with those results, a recent report described the spatial structure of BNip3 in a membrane-mimicking lipid environment, showing that BNip3 homodimers can form an ion-conducting pathway in the membrane. 25 In line with these studies, BNip3 translocation into the mitochondrial membrane and BNip3 dimerization may elicit the Dc m loss observed in animal and cell culture models of HD and in myoblasts extracted from HD patients.
We observed increased levels of BNip3 homodimers in the mitochondrial fractions of all HD models investigated in our studies, including human HD myoblasts, R6/2 and YAC 128 mouse brains and transfected cell lines. These data suggest that BNip3 dimerization may be a crucial step in the BNip3 activation process induced by mutant htt expression, even if a role for the monomeric form of BNip3 in mitochondrial damage cannot be ruled out. Indeed, we observed a significant accumulation of BNip3 monomers in SHSY5Y cells on mutant htt expression. Moreover, an increased resistance of the BNip3 monomeric form to PK digestion was observed in lysates from R6/2 brains and HD myoblasts. Whether some of these monomers were derived from partial dissociation of the homodimers under denaturing and reducing conditions or rather represented the molecular precursors of dimers cannot be assessed.
If our hypothesis positing that BNip3 has a role in Dc m loss in HD is correct, then the inhibition of BNip3 expression and/or BNip3 translocation and dimerization in HD cells should result in the increase in mitochondrial Dc m . BNip3DTM is a dominant-negative mutant lacking the transmembrane domain required for BNip3 translocation and integration into the OMM. 23, 24 We observed that expression of BNip3DTM and simultaneous downregulation of endogenous BNip3 by RNA interference in human HD muscle cells rescued the Dc m loss induced by mutant htt. These data support a role for BNip3 in htt-induced mitochondrial damage and point to a new potential gene therapy approach for HD. It is important to note that BNip3 knockout mice are viable and lack a pathological phenotype; 39 thus, the inhibition of BNip3 function by RNA interference or by overexpression of the dominant-negative mutant BNip3DTM may have neuroprotective effects without causing adverse side effects.
One question that remains unanswered is how mutant htt induces BNip3 activation. Previous reports have shown that BNip3 association with mitochondria is strongly stabilized by acidosis 14, 40 or by an increased cytosolic calcium concentration. 18 Both conditions may occur in HD cells, causing BNip3 stabilization and integration into the OMM, but one more intriguing possibility should also be considered: in light of the fact that htt can localize to the mitochondria by loosely associating with the OMM, we may hypothesize that htt binds directly or indirectly to BNip3. Future studies will aim at elucidating these and other potential mechanisms underlying the effects of mutant htt on BNip3.
Materials and Methods
Muscle cell cultures. Muscle cell cultures were obtained from human biopsy specimens, as described previously. 8 Demographic and clinical data of HD patients and control subjects are reported in Supplementary Table 1.
Animal models. Transgenic R6/2 mice and wild-type CBA animals were originally obtained from the Jackson Laboratory (Bar Harbor, ME, USA) and from a colony established in the animal facility of the Department of Biomolecular Science and Biotechnology, University of Milan. Two additional R6/2 mouse brains were kindly donated by Dr. Ferdinando Squitieri (IRCCS Neuromed, Pozzilli (IS)). YAC128 mice (FVB-Tg(YAC128)53Hay/J) were originally obtained from the Jackson Laboratory and maintained in the Health Sciences Laboratory Animal Services at the University of Alberta. All mice were handled following institutional guidelines.
Plasmids. Plasmids encoding Myc-tagged htt exon-1, wild-type (9 CAG) or mutant (60 CAG), were generated by in-frame insertion of a PCR-amplified DNA fragment encoding htt exon-1 into the pcDNA4-Myc-HIS vector (Invitrogen, Carlsbad, CA, USA). Plasmid pTarget-BNip3DTM was created by introducing a stop codon (TAG) after amino acid 161, using the QuikChange kit (Stratagene, La Jolla, CA, USA). To prevent BNip3DTM from being silenced by siRNA against endogenous BNip3, three conservative single-nucleotide mutations were introduced (i.e., a468c, c471t and a477c).
All DNA constructs were verified by sequencing with the BigDye Terminator kit (Applied Biosystems, Foster City, CA, USA).
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